A detailed history of Massachusetts Financial Services CO transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Massachusetts Financial Services CO holds 2,905,705 shares of VRTX stock, worth $1.15 Billion. This represents 0.42% of its overall portfolio holdings.

Number of Shares
2,905,705
Previous 2,746,012 5.82%
Holding current value
$1.15 Billion
Previous $1.29 Billion 4.99%
% of portfolio
0.42%
Previous 0.41%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$460.0 - $505.78 $73.5 Million - $80.8 Million
159,693 Added 5.82%
2,905,705 $1.35 Billion
Q2 2024

Aug 09, 2024

SELL
$392.81 - $485.53 $22.9 Million - $28.2 Million
-58,176 Reduced 2.07%
2,746,012 $1.29 Billion
Q1 2024

May 14, 2024

SELL
$407.69 - $446.08 $335 Million - $367 Million
-821,614 Reduced 22.66%
2,804,188 $1.17 Billion
Q4 2023

Feb 08, 2024

SELL
$343.0 - $410.68 $91.2 Million - $109 Million
-265,992 Reduced 6.83%
3,625,802 $1.48 Billion
Q3 2023

Nov 08, 2023

SELL
$338.18 - $362.46 $16.7 Million - $17.9 Million
-49,327 Reduced 1.25%
3,891,794 $1.35 Billion
Q2 2023

Aug 09, 2023

SELL
$314.42 - $351.91 $32.7 Million - $36.6 Million
-103,910 Reduced 2.57%
3,941,121 $1.39 Billion
Q1 2023

May 10, 2023

SELL
$283.23 - $323.1 $18.8 Million - $21.5 Million
-66,524 Reduced 1.62%
4,045,031 $1.27 Billion
Q4 2022

Feb 13, 2023

SELL
$285.76 - $321.48 $67.2 Million - $75.6 Million
-235,176 Reduced 5.41%
4,111,555 $1.19 Billion
Q3 2022

Nov 09, 2022

BUY
$273.83 - $305.53 $1.26 Million - $1.41 Million
4,619 Added 0.11%
4,346,731 $1.26 Billion
Q2 2022

Aug 09, 2022

BUY
$234.96 - $292.55 $194 Million - $242 Million
826,959 Added 23.53%
4,342,112 $1.22 Billion
Q1 2022

May 11, 2022

BUY
$221.42 - $260.97 $71 Million - $83.6 Million
320,475 Added 10.03%
3,515,153 $917 Million
Q4 2021

Feb 10, 2022

BUY
$177.01 - $223.45 $8.04 Million - $10.2 Million
45,438 Added 1.44%
3,194,678 $702 Million
Q3 2021

Nov 10, 2021

SELL
$181.39 - $202.99 $824,780 - $922,995
-4,547 Reduced 0.14%
3,149,240 $571 Million
Q2 2021

Aug 13, 2021

BUY
$187.49 - $221.1 $55.7 Million - $65.7 Million
297,171 Added 10.4%
3,153,787 $636 Million
Q1 2021

May 13, 2021

BUY
$207.02 - $241.31 $46.1 Million - $53.7 Million
222,507 Added 8.45%
2,856,616 $614 Million
Q4 2020

Feb 12, 2021

BUY
$207.01 - $276.09 $152 Million - $203 Million
733,952 Added 38.63%
2,634,109 $623 Million
Q3 2020

Nov 12, 2020

BUY
$255.65 - $303.1 $23.5 Million - $27.8 Million
91,876 Added 5.08%
1,900,157 $517 Million
Q2 2020

Aug 11, 2020

BUY
$225.48 - $295.8 $131 Million - $172 Million
581,495 Added 47.4%
1,808,281 $525 Million
Q1 2020

May 14, 2020

BUY
$199.77 - $247.81 $20.6 Million - $25.6 Million
103,158 Added 9.18%
1,226,786 $292 Million
Q4 2019

Feb 13, 2020

SELL
$166.71 - $223.91 $16.1 Million - $21.6 Million
-96,312 Reduced 7.89%
1,123,628 $246 Million
Q3 2019

Nov 05, 2019

SELL
$166.23 - $187.09 $120 Million - $135 Million
-720,436 Reduced 37.13%
1,219,940 $207 Million
Q2 2019

Aug 14, 2019

SELL
$164.61 - $190.37 $5.8 Million - $6.7 Million
-35,218 Reduced 1.78%
1,940,376 $356 Million
Q1 2019

May 13, 2019

BUY
$163.73 - $194.7 $10.6 Million - $12.6 Million
64,583 Added 3.38%
1,975,594 $363 Million
Q4 2018

Feb 08, 2019

BUY
$151.91 - $192.21 $10.8 Million - $13.7 Million
71,366 Added 3.88%
1,911,011 $317 Million
Q3 2018

Oct 25, 2018

BUY
$167.73 - $192.74 $29.5 Million - $33.9 Million
176,093 Added 10.59%
1,839,645 $355 Million
Q2 2018

Jul 30, 2018

BUY
$145.72 - $169.96 $20.9 Million - $24.4 Million
143,730 Added 9.46%
1,663,552 $283 Million
Q1 2018

May 04, 2018

BUY
$151.6 - $177.13 $230 Million - $269 Million
1,519,822 New
1,519,822 $248 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $102B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Massachusetts Financial Services CO Portfolio

Follow Massachusetts Financial Services CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Massachusetts Financial Services CO , based on Form 13F filings with the SEC.

News

Stay updated on Massachusetts Financial Services CO with notifications on news.